Trial · NCT07896330
Flavored Electronic Nicotine Delivery Systems to Lower Smoking and Exposure to Tobacco Toxicants Among Cigarette Smokers Interested in Quitting, REFLECT Trial
NCT07896330, Not applicable, Not yet recruiting, Roswell Park Cancer Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Flavored Electronic Nicotine Delivery Systems to Lower Smoking and Exposure to Tobacco Toxicants Among Cigarette Smokers Interested in Quitting, REFLECT Trial. Trials, record NCT07896330. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896330
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Flavored Electronic Nicotine Delivery Systems to Lower Smoking and Exposure to Tobacco Toxicants Among Cigarette Smokers Interested in Quitting, REFLECT Trial
- NCT number
- NCT07896330
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 286 participants, estimated
- Lead sponsor
- Roswell Park Cancer Institute
- Conditions
- Tobacco Cessation, Electronic Nicotine Delivery Systems
- Interventions
- Vaping - Fruit flavored ENDS, Biospecimen Collection, Vaping - tobacco flavored ENDS
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Cigarettes per day (CPD) from baseline to 12 month follow up visit | baseline to 12 months | CPD reduction at month 12 compared to baseline |
| Primary | Measure Change in biomarker concentration NNAL | From Baseline to 12 months | urinary measure of NNAL |
| Secondary | Proportion of participants achieving a greater than or equal to 50% reduction in Cigarettes Per Day | Baseline to 12 months | Will be summarized by treatment group and compared between participants who received fruit-flavored ENDS and those who received tobacco-flavored ENDS. |
| Secondary | Proportion of participants achieving a 100% reduction in CPD | Baseline to 12 months | Self reported - Will be summarized by treatment group and compared between participants who received fruit-flavored ENDS and those who received tobacco-flavored ENDS. |
| Secondary | Proportion of participants achieving a greater than or equal to 50% reduction in urinary NNAL | Baseline to 12 months | Will be summarized by treatment group and compared between participants who received fruit-flavored ENDS and those who received tobacco-flavored ENDS |
| Secondary | Proportion of participants achieving a 100% reduction in NNAL | Baseline to 12 months | Will be summarized by treatment group and compared between participants who received fruit-flavored ENDS and those who received tobacco-flavored ENDS |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DA065590 | Assessing whether use of fruit flavored ENDS relates to smoking reductions in people who smoke cigarettes: A data triangulation approach to maximize internal and external validity | Goniewicz, Maciej Lukasz; Kasza, Karin A | ROSWELL PARK CANCER INSTITUTE CORP | NATIONAL INSTITUTE ON DRUG ABUSE | 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896330
GET https://conductscience.org/api/trials/v1/NCT07896330/registered